Endoscopic Ultrasound (EUS) Guided-Celiac Plexus Neurolysis (CPN) in Unresectable Pancreatic Cancer

Completed · Not applicable

Conditions studied: Pain, Pancreatic Cancer

In brief

The purpose of this study is to examine endoscopic ultrasound guided celiac plexus neurolysis (CPN) with analgesic therapy in patients with unresectable pancreatic cancer as it applies to decreasing the severity of abdominal pain when compared to analgesic therapy alone.

Key facts

Study ID

NCT00968175

Run by

University of Alabama at Birmingham

People needed

60

Starts

2009-06-01

Expected to finish

2013-12-01

Last updated by the study team

2014-06-04

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or Female
• Age ≥19 yrs old
• Abdominal pain typical for pancreatic cancer ≥3/10
• Abdominal CT radiologically consistent with the diagnosis of pancreatic cancer
• Pancreatic cancer confirmed by FNA during EUS
• Inoperability of pancreatic cancer as determined during EUS or prior CT

You may not qualify if…

• Age < 19 yrs old
• Unable to safely undergo EUS for any reason
• Coagulopathy (prolongation of prothrombin time > 18 sec, thrombocytopenia <80,000 platelets/ml)
• Previous CPN or other neurolytic block that could affect pancreatic cancer -related pain or had implanted epidural or intrathecal analgesic therapy
• Another cause for abdominal pain such as pseudocyst, ulcer or other intra-abdominal disorder
• Potential patient noncompliance (refusing to follow schedule of events)
• Active alcohol or other drug use or significant psychiatric illness
• Pregnant or breastfeeding
• Unable to consent
• Non-English speaking

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• Florida Hospital — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.